CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Ruxolitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04492618
NCT04492618Phase 2Completed
CompareCT.gov

Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

Aaron R. Mangold·interventional·Posted Jul 30, 2020·Updated Feb 8, 2023

In Brief

A Phase 2 clinical trial evaluating Ruxolitinib for Necrobiosis Lipoidica. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This research study is evaluating the safety and efficacy of a topical drug treatment "Ruxolitinib" in treating Necrobiosis Lipoidica (NL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNecrobiosis Lipoidica
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJul 30, 2020
Enrollment StartSep 29, 2020
Primary CompletionMar 16, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.9 years ago

Interventions

Ruxolitinibdrug

Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica